CRISPR Edited iPSC Derivative Cell Therapy FT538: FDA Approved FORIND
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fate Therapeutics is a clinical biopharmaceutical company dedicated to the development of cell immunotherapyThe company recently announced that the U.SFDA has approved its application for a new research drug (IND) to allow clinical trials of FT538 (CRISPR-ediphotod iPSC-derived cell therapy) to treat tumorsFT538 is a natural killer cell (NK) cancer immunotherapy derived from induced pluripotent stem cells (iPSC) and engineered with three functional components to enhance innate immunity: a new high affinity CD16 (hnCD16) Fc receptor; The company plans to begin a clinical study of FT538 for the treatment of acute myeloid leukemia (AML) and to use it in conjunction with daratumab monoclonal antibody therapy for the treatment of multiple myeloma"We are pleased to extend iPSC-derived cell therapy to multiple myeloma with a still high recurrence rate," said Scott Wolchko, President and CEO of Fate TherapeuticsClinical data show that even in the early stages of myeloma, NK cell-mediated immunodeficiency is still evident and accumulates through disease progressionWe believe that administering FT538 to patients restores innate immunity and is more effective in anti-cancer when used in combination with certain standard care methods, such as monoclonal antibodies."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
